HCA Healthcare, Inc. (NYSE: HCA) reported its financial and operational results for Q2 2024, ending June 30, 2024. Here are the key highlights: Second Quarter Highlights: Six-Month Summary: Balance Sheet & Cash Flow: Dividend Declaration: Revised 2024 Guidance: Outlook:The revised…
CVS Caremark®, the top pharmacy benefit manager and a division of CVS Health® (NYSE: CVS), has announced a new commitment to enhance pharmacy benefits for American businesses, unions, and health plans. This initiative aims to offer greater transparency, lower drug…
Bristol Myers Squibb (NYSE: BMY) has announced its financial results for Q2 2024. Highlights: Second Quarter Financials: Product Revenue Highlights: Product and Pipeline Updates: Financial Guidance for 2024: Bristol Myers Squibb’s Q2 2024 results reflect ongoing efforts to drive growth…
Geron Corporation (Nasdaq: GERN) has announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include RYTELO™ (imetelstat) as a recommended treatment for symptomatic anemia in lower-risk myelodysplastic syndromes (MDS). The updated guidelines categorize RYTELO…
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced a new study in the Journal of Clinical Oncology showcasing the effectiveness of its personalized molecular residual disease (MRD) test, Signatera, for monitoring Merkel cell carcinoma (MCC). The…
HU Group Holdings Inc. and its subsidiary, Fujirebio, have announced the launch of the Lumipulse G GFAP assay for use on the fully automated, random-access LUMIPULSE® G immunoassay systems. This research-use only (RUO) assay is now available in the United…
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology with its Omnipod® products, has announced preliminary revenue results for Q2 2024, ending June 30. Full financial results will be reported on August 8, 2024, followed by a conference…
Schrödinger, Inc. (Nasdaq: SDGR), renowned for its physics-based computational platform, is launching a new initiative to enhance early-stage drug discovery by predicting toxicology risks. This project aims to improve drug development candidates by minimizing the risk of adverse effects from…
The Althaia Foundation is launching an innovative project to prevent falls in frail hospitalized patients using artificial intelligence. In collaboration with Robbie AI, this initiative aims to help healthcare professionals anticipate fall risks and take preventive actions. The pilot study…
Amprion, a leader in advancing the diagnosis of neurodegenerative disorders through seed amplification testing, is unveiling its new line of cerebrospinal fluid (CSF) biomarker panels under the SAAmplify brand. These panels provide physicians and patients with the most comprehensive biomarkers…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in…
The Glycocalyx Research Institute is excited to announce groundbreaking results from a recent study exploring the impact of microvascular health—comprising the vast network of tiny capillaries in the body—on acute side effects from radiation therapy in breast, prostate, and head…